The objective of the study was to evaluate the budget impact of shifting the treatment for menorrhagia in Canadian hospitals from rollerball to thermal balloon ablation. Thermal balloon ablation procedures can be completed in an ambulatory care setting as compared to rollerball procedures, which must be carried out in the operating room. The aim of this study was to determine whether shifting procedures from rollerball to thermal balloon ablation would present a hospital with cost savings on a per patient basis. METHODS: A budget impact model was created and populated using case-costing data from several large Canadian hospitals. The two procedures were compared in terms of device cost, use of resources and nursing costs. The cost of treatment using rollerball and thermal balloon ablation were compared to determine the number of procedures that could be completed using each device for the same total cost. RESULTS: Based on model calculations the total cost per patient to treat menorrhagia using rollerball is $1,977.58 and the total cost per patient to treat menorrhagia using thermal balloon ablation is $1,415.46. The use of thermal balloon ablation allows for a hospital savings of $562.12 per patient treated. The use of thermal balloon ablation would enable a Canadian hospital to treat approximately 70 patients with menorrhagia for the same total cost as treating 50 patients with rollerball. CONCLUSIONS: The use of thermal balloon ablation for the treatment of menorrhagia allows for a cost savings per patient when compared with rollerball.
OBJECTIVES: Use of vascular closure devices for sealing the femoral artery following percuatneous coronary diagnostic and interventional procedures has become a routine practice. The collagen-based closure device system Angio-Seal™ has been shown to be effective in decreasing time to hemostasis after coronary procedures. Budgetary impact of replacing manual compression with Angio-Seal™, however, has not been explored. We sought to evaluate the budget impact of using Angio-Seal™ from the hospital perspective as it relates to clinical and economic outcomes. METHODS: A customizable Excel®-based budget impact model was built from a hospital perspective for a hypothetical cohort of 400 patients (200 interventional and 200 diagnostic) over a period of one year. Cost components included device cost, facility cost (recover room costs) and nursing cost. A decision tree model was utilized to convert the expected probabilities of vascular complications into expected costs. Probabilities and costs were derived from published meta-analyses and observational studies. Costs were converted to 2011 US dollars. Sensitivity analysis was carried out over reported ranges of values for major inputs of the model. RESULTS: Using Angio-Seal™ in 100% of the cases resulted in estimated cost savings of $255,498 per year compared to manual compression. Angio-Seal™ usage resulted in cost savings for both interventional and diagnostic cases. Cost savings were most sensitive to the variation in time and costs spent in the recovery room as well as to the probabilities of groin bleeding and retroperitoneal hemorrhage. Results were robust to changes in input variables. CONCLUSIONS: Analysis shows that Angio-Seal™ represents a potential cost saving option for institutions to achieve hemostasis after percutaneous coronary procedures without increasing the risk of vascular complications. Given the current evidence on safety and effectiveness of same-day discharge percutaneous coronary procedures, Angio-Seal™ adds a potential cost savings dimension that can facilitate adoption of this clinical practice.
PMD13 ASSESSING THE BUDGET IMPACT OF USING SCANBAG® IN CT IN SIX EUROPEAN COUNTRIES
Nivelle E 1 , Mathou F 2 , Lamotte M 1 1 IMS Health Consulting Group, Vilvoorde, Belgium, 2 Guerbet SA, Villepinte, France OBJECTIVES: Contrast agents for computer tomography (CT) are presented in glass or plastic vials or syringes. Those containers take a lot of volume and are of considerable weight resulting in important costs for storage and waste processing. There is also a risk for injuries with sharp lips and spilling due to breakage. Those containers need the use of small medical devices to allow injection of contrast agents. The ScanBag® container was developed to overcome these problems. The objectives of this study were to assess the impact on the hospital budget of using Scanbag® instead of other containers. METHODS: According to the Ispor recommendations for budget impact models (BIMs), we developed a BIM to demonstrate the economical advantage of using contrast agents in ScanBag® from a hospital perspective. Resource use in terms of broken products, injuries, storage, waste management, small medical devices, and mono-or multipatient use for each presentation type were collected via literature and expert interviews in public and private radiology centers in France, Belgium, Germany, Italy, Spain and the United Kingdom. RESULTS: Replacing 1000 glass vials of 200 ml iobitridol by the same volume in ScanBag® reduces broken products and injuries by 100%, storage space by 43.8% and waste weight by 89.4%. Total cost savings for this simulation range from €7076 in Germany to €8484 in Italy when costs of broken products, injuries, storage, waste management and small medical devices are considered. Depending on the injector used, cost savings of up to €6,700 can be obtained for small medical devices. CONCLUSIONS: Only in changing glass vials to ScanBag®, costs for hospitals can be reduced through savings in broken products, injuries, storage and waste management. Largest cost savings are made on small medical devices.
PMD14 ESTIMATING THE ECONOMIC BURDEN OF ATRIAL FIBRILLATION IN SELECTED DEVELOPING COUNTRIES
Rizzo JA 1 , Mallow P 2 , Waters H 2 , Cirrincione A 3 1 Stony Brook University, Port Jefferson, NY, USA, 2 S2 Statistical Solutions, Inc., Cincinnati, OH, USA, 3 Biosense Webster, Inc, Diamond Bar, CA, Belgium OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease characterized by uncoordinated atrial activation involving rapid, irregular heartbeats (Fuster et al. 2006) . AF patients are likely to have co-morbidities such as congestive heart failure (CHF) and stroke (Lee et al. 2008) . The prevalence of AF in adults is Ͻ1% in adults Ͻ55 years, but increases to as much as 10% by age 80 (Go et al. 2001) . The purpose of this study was to estimate the economic burden of AF in selected developing countries based on prevalence and direct health care costs. METHODS:
The economic burdens of AF in Brazil, China, India, Russia, and Turkey were calculated based on prevalence rates identified via a literature search. Annual probabilities for health care interventions and related costs (e.g.: management of AF, stroke and CHF), and associated disability costs were included in the model. The adult population was adjusted for the percentage of the population who had access to health care. If cost data were unavailable, costs were imputed based on the ratio of per capita health expenditures between the United States and country of interest. Sensitivity analysis was performed for the health care accessible population. RESULTS: The prevalence of AF in adults in the countries studied was: 226,000 in Turkey; 430,000 in Brazil; 497,000 in Russia; 778,000 in India; and 1.8 million in China. The estimated annual economic burden of AF was: 159 million in Turkey; 412 million in Brazil; 5.7 billion in Russia; 1.25 billion in India; and 2.5 billion in China (2010 local currencies). Sensitivity analysis revealed that the results could be substantially higher. CONCLUSIONS: The economic burden of AF in developing countries is potentially substantial given the large populations in these countries. Proper management of AF is becoming increasingly important in countries where access to health care has constantly been improved.
PMD15 THE ECONOMIC BURDEN OF ATRIAL FIBRILLATION AMONG ELDERLY POPULATIONS IN SELECTED DEVELOPED COUNTRIES
Rizzo JA 1 , Mallow P 2 , Waters H 2 , Cirrincione A 3 1 Stony Brook University, Port Jefferson, NY, USA, 2 S2 Statistical Solutions, Inc., Cincinnati, OH, USA, 3 Biosense Webster, Inc, Diamond Bar, CA, Belgium OBJECTIVES: Atrial fibrillation (AF) is an arrhythmia that progressively worsens and is characterized by uncoordinated atrial activation involving a rapid and irregular heart rate (Fuster et al. 2006) . AF patients are likely to have concomitant congestive heart failure (CHF) and stroke (Lee et al. 2008) . The prevalence of AF in adults Ն65 years is 5 -6%, increasing with age (Go et al. 2001) . The purpose of this study was to estimate the economic burden of AF in selected developed countries based on prevalence and direct health care costs. METHODS: The economic burden of AF in the United States (US), Canada, Germany, France, United Kingdom and Italy was modeled based on prevalence rates identified via a literature search. Annual probabilities of receiving health care treatment and associated costs for AF, stroke and CHF, and related disability costs were included in the model. If cost data were unavailable, the costs were imputed based on the ratio of annual per capita health expenditures between the United States and the country of interest. Cost estimates were calculated in 2010 rates of the local currencies. RESULTS: The prevalence of AF in adults aged Ն65 in the countries studied was: 172,000 in Canada; 328,000 in the United Kingdom; 348,000 in France; 391,000 in Italy; 533,000 in Germany; and 1.6 million in the United States. The estimated annual economic burden of AF was: 597 million in Canada; 596 million in the United Kingdom; 1.23 billion in France; 840 million in Italy; 1.58 billion in Germany; and 9.75 billion in the United States (2010 local currencies). CONCLUSIONS: The economic burden of AF in developed countries is substantial, and is expected to grow as the population ages. Early detection and appropriate management of AF may help reduce this economic burden.
PMD16 FORECASTING THE PREVALENCE AND ECONOMIC BURDEN OF ATRIAL FIBRILLATION IN SELECTED COUNTRIES, 2010 -2025
Rizzo JA 1 , Mallow P 2 , Waters H 2 , Cirrincione A 3 1 Stony Brook University, Port Jefferson, NY, USA, 2 S2 Statistical Solutions, Inc., Cincinnati, OH, USA, 3 Biosense Webster, Inc, Diamond Bar, CA, USA OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease characterized by uncoordinated atrial activation involving a rapid and irregular heartbeat (Fuster et al. 2006) . The prevalence of AF is Ͻ1% in adults Ͻ55 years old, but increases to as much as 10% by age 80 (Go et al. 2001) . The purpose of this study was to forecast the incidence of AF in selected countries for 2015, 2020 and 2025 based on predicted prevalence. METHODS: The prevalence of AF in Brazil, Canada, China, India, the United Kingdom and United States (US) was forecasted based on prevalence rates identified via a literature search and 2010 estimates of AF prevalence. Population forecasts for the selected countries were taken from United Nations Department of Economic and Social Affairs forecasts. The adult population was adjusted for the percentage of the population with access to health care. The model assumed current age-adjusted prevalence rates would remain constant through 2025. One-way sensitivity analysis was performed for the health care accessible population and the country forecasted population. RESULTS: The prevalence and economic burden is forecasted to increase from 0% to 2% per year in the selected countries. In 2025, the prevalence and economic burden ranged from 282,000 and 245 million Lira in Turkey to 2.68 million and $17 billion in the United States. The burden is reported in 2010 local currencies. Sensitivity analyses revealed that prevalence in developing countries were most affected by health care accessibility. In developed countries, prevalence was most affected by forecasted population growth.
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